A Missed Opportunity in Expanded Access Limits Real-World Insights
An expanded access protocol for gemtuzumab ozogamicin gathered only safety data, no efficacy data, limiting insights into real-world use.
Hematologic Cancers News
HEMATOLOGIC CANCER ADVISOR
Hematologic Cancers News
Changes in Management of CLL Due to COVID-19 Noted in Italy
The management of CLL, including delays in work-up and treatment, and modifications to clinical trials, have been implemented across Italy in response to the COVID-19 pandemic.
Considerations for the Diagnostic Work-Up of Breast Implant–Associated Lymphoma
Flow cytometry may provide an efficient, sensitive, and specific tool for the differential diagnosis of breast implant–associated ALCL, but a cell block may be able to answer additional questions about the disease.
Treating Strategies for Patients With Relapsed/Refractory Acute Myeloid Leukemia
Although numerous clinical studies have aimed to treat AML, most results have been disappointing, according to authors of a publication in Blood.
Study Finds Vancomycin Increased Risk for Cytomegalovirus Reactivation After Hematopoietic Cell Transplant
A retrospective study of CMV-seropositive adults receiving allogeneic HCT and CMV-seronegative HLA-matched sibling donors found that vancomycin exposure before HCT increased the risk for CMV reactivation.
Methotrexate-Induced Acute Kidney Injuries in Patients With Hematologic Malignancies
Upon starting methotrexate treatment, LDH and albumin levels may be signals for AKIs in patients with hematologic malignancies.
Incidence of VTE, Major Bleeding High in Primary CNS Lymphoma
VTE risk up with chemotherapy, radiation therapy; major bleeding risk up with PE, proximal DVT.
Study Finds Higher Incidence of Atrial Fibrillation With Ibrutinib Therapy
Patients with chronic lymphocytic leukemia who are treated with ibrutinib may have a higher incidence of atrial fibrillation than previously thought.
Addition of Rituximab to Chemotherapy for Pediatric High-Risk, Mature B-Cell NHL
For pediatric high-risk B-cell NHL, adding rituximab to standard LMB chemotherapy prolongs event-free and overall survival but may increase adverse events.
Disease-Free Survival Not Improved With Intrathecal Triple Therapy in B-Cell ALL
A study compared the effects of intrathecal triple therapy to intrathecal methotrexate on disease-free survival among patients with B-ALL.
Ruxolitinib in Glucocorticoid-Refractory Acute Graft-vs-Host Disease After Allogeneic Stem Cell Transplantation
For patients with GVHD, ruxolitinib improves efficacy outcomes compared with 9 other commonly used options.
Could Checkpoint Blockade Be Useful in Non-Hodgkin Lymphoma After All?
A study suggested that the immunotherapy could be sensitizing non-Hodgkin lymphoma patients to subsequent therapies.
Xpovio Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The FDA has granted accelerated approval of Xpovio® (selinexor; Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Direct-to-Drug Screening Tool Allows for Precision Medicine in Multiple Myeloma
An assay from Mayo Clinic researchers screens multiple myeloma drugs to see how cells with different biomarkers and pretreatment histories react.
Tazverik Granted Accelerated Approval for Follicular Lymphoma
Tazverik, a methyltransferase inhibitor, is already indicated for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
When COVID-19 Meets CLL: Limited Evidence Offers Some Hope for Good Outcomes
A recent small study is hypothesis generating and highlights the need for COVID-19-related studies with large cohorts of CLL patients.
Identifying Optimal Immunochemotherapy for Patients With Mantle Cell Lymphoma
Few population-based studies have compared treatment approaches in the setting of mantle cell lymphoma.
Addition of Venetoclax to Azacitidine Associated With Clinically Significant OS Benefit in AML
The addition of venetoclax to azacitidine was associated with a 34% reduction in risk of death.
Addition of Isatuximab to Kd Deepens Responses and Extends PFS in R/R Multiple Myeloma
The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.
Risk of Thrombosis With Treatments for Newly Diagnosed Multiple Myeloma
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
